AzTrials
AzTrials

Retinopathy of PrematurityNCT05132257

Genetic Polymorphism and Retinopathy of Prematurity: Correlation of Clinical Presentations and Severity

An observational study of Retinopathy of Prematurity and Genetic Polymorphism, run by Chang Gung Memorial Hospital at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Study Aim and Goals 1. Evaluate the correlation between genetic polymorphism and ROP development 2. To study the possibility if there are any specific genetic polymorphisms that lead to poor outcome or recurrence of ROP after treatment. Read more about this study

Who is it for?
Ages 3 to 12 yearsHealthy volunteers can take part
What is being tested?
Severe ROP
How many people
500 participants
Where
1 siteTaiwan
Study dates
12 Apr 2021to 31 Mar 2024
How long will I take part?
3 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 12 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: We recruit the children born at Linkou and Taipei branches of Chung Gung Memorial Hospital in the study period, who are willing to undergo series of ophthalmologic examination

Who may be able to join

  • 1. Infants born at Linkou and Taipei branches of Chang Gung Memorial Hospital during the study period.

Who cannot join

  • Parents unwilling to participate in the study
  • Incomplete medical records.
  • Folllow-up period less than 6 months
  • Other ocular diagnosis including glaucoma, cataract, FEVR, etc.

Trial locations and contacts

1 site in 1 country.

Wu WeiChi, M.D., PhD. contact

886-3-3281200 ext. 8666

weichi666@gmail.com

Taiwan1 site, 1 recruiting
  • Department of Ophthalmology, Chang Gung Memorial Hospital.

    Linkou District, Taoyuan, 33305

    weichi wu, M.D., PhD., 886-3-3281200 ext. 8666, weichi666@gmail.com

    Recruiting

Other trials in Taiwan

About this study

Study Aim and Goals

  1. Evaluate the correlation between genetic polymorphism and ROP development
  2. To study the possibility if there are any specific genetic polymorphisms that lead to poor outcome or recurrence of ROP after treatment.
Read the detailed description

Background:

The preterm neonate, especially the low birth weight infant, is at a greater risk to develop disorders in multiple organ systems because of immaturity. Retinopathy of prematurity (ROP) is a disorder of the developing retina of low birth weight preterm infants that has the potential to lead to blindness. Although the pathogenesis and etiology of ROP remains unclear, many causative factors have been proposed. Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis in fetal life. In humans, polymorphisms in the VEGF gene have been reportedly associated with proliferative diabetic retinopathy and age-related degeneration. These retinal diseases might share the disease process of vasculopathy with ROP. Besides risk factors specifically associated with preterm birth, the activation of pro-inflammatory cytokines has been suggested to contribute to ROP development. Tumor necrosis factor (TNF)-α is one of the major cytokines in inflammation. Its expression was up-regulated in retinal neovascularization in animal models and proliferative eye diseases in humans. Many researchers suggest that TNF-α may affect retinal angiogenesis and predispose preterm infants for later development of ROP. Recent studies showed the possible correlation between ROP and polymorphism in VEGF (-460 T/C, +936 C/T, -634 G/C, and -2578 C/A), or TNF-α (-308 G/A). However, these studies focused on western populations. In our study, we will analyze the relationships among severity, treatment outcomes, and genetic polymorphism findings in ROP.

Study Aim and Goals

  1. Evaluate the correlation between genetic polymorphism and ROP development
  2. To study the possibility if there are any specific genetic polymorphisms that lead to poor outcome or recurrence of ROP after treatment.

Study Design Participants: We plan to recruit the children born at Linkou and Taipei branches of Chung Gung Memorial Hospital in 2009-2018, who are willing to undergo series of ophthalmologic examinations.

Study period: April, 2021 to March, 2024. A prospective cohort study Inclusion criteria: All children who were born at Linkou and Taipei branches of Chung Gung Memorial Hospital during the period of 2009 to 2018.

Exclusion criteria: If the parents were not willing to participate the study, or the medical records were not complete, or the follow period was less than 6 months.

Estimated patients' numbers: about 500 babies/3 years Methods: Participants will receive series of ocular exams, including: cycloplegic refractions, strabismus exams, exams of intraocular pressure, slit lamp exam, fundus exam, axial length measurement, etc. After the parent's and the participant's agreement, we will have a blood test of 3 ml and undergo DNA collection (Oragene-DNA; DNA-Genotek, Ottawa, Canada) by study personnel. We will analyze around 10 SNPs from each of candidate genes in our study.

According to patients' previous records and images, subjects will be classified as cases and controls. "Cases" will be infants with severe treatment-requiring ROP (defined as type-1 ROP [zone I, any stage, with plus disease; zone I, stage 3, without plus disease; or zone II, stage 2 or 3, with plus disease] or worse). "Controls" will be full-term babies without other retinal disorder, infants with no ROP or with mild ROP less severe than type-1 ROP, who are within the same birth weight group (e.g., <1000 grams or ≥1000 grams). After matching genetic results and structural outcomes, we will analyze whether any specific genetic polymorphism had higher presentations in treatment-requiring ROP patients. Also, secondary analysis will focus on the difference between recurrent/poor outcome cases and other cases.

Statistical Analysis: Continuous variables will be analyzed with independent-t or paired-t test. One-way ANOVA will be used to compare three or more groups. Ordinal variables will be analyzed with Wilcoxon rank sum test (two independent samples) or Wilcoxon signed rank test (tow paired samples). Categorical variables will be analyzed with Chi-square test or Fisher's exact test. A multivariable logistic regression model will be constructed to assess the association between myopia prevalence and all studied risk factors. P value <0.05 will be considered statistically significant.

Being tested
Severe ROP
Keywords
Retinopathy of prematurity, genetic polymorphism
Medical subject headings
Retinopathy of Prematurity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Severe ROPProcedure or surgery

    Also called Type 1 ROP

    The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.

Study groups in NCT05132257
Study groupRoleWhat they receive
PM No-ROPPremature without retinopathy of prematurity. Prematurity was defined as birth at < 37 weeks gestation.
Mild ROPPrematurity with mild retinopathy of prematurity. ROP not needing treatment. Prematurity was defined as birth at < 37 weeks gestation.
Severe ROPPrematurity with type 1 retinopathy of prematurity. Prematurity was defined as birth at < 37 weeks gestation.
Receives: Procedure: Severe ROP
FulltermHeathal fullterm.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. SNP Selection, Detection, and Genotyping

    We will analyze around 10 SNPs from each of 53 candidate genes in our study population. Genotyping of 500 selected SNPs will be performed by TaqMan genotyping assays (Applied Biosystems, Foster City, CA) on the 7900HT Fast Real-Time PCR System (384-well platform). Primary outcome comprises frequency of mutations in percentage ratio and risk profile analysis (odds ratio).

    Measured: 2021-2024

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Nov 2021
  2. Study start12 Apr 2021
  3. Primary completion31 Mar 2024 (estimated)
  4. Study completion31 Mar 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
500 participants (estimated)
Target duration
3 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT05132257
Sponsor's protocol ID
202001715A3
Status last verified
May 2023
First submitted
2 Nov 2021
Last updated
6 May 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Retinopathy of Prematurity and Genetic Polymorphism, run by Chang Gung Memorial Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Wu WeiChi, M.D., PhD. (886-3-3281200 ext. 8666, weichi666@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

SNP Selection, Detection, and Genotyping (time frame: 2021-2024). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in